GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entero Therapeutics Inc (FRA:366) » Definitions » Short Interest

Entero Therapeutics (FRA:366) Short Interest


View and export this data going back to 2018. Start your Free Trial

What is Entero Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Entero Therapeutics's Short Interest

For the Biotechnology subindustry, Entero Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entero Therapeutics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entero Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Entero Therapeutics's Short Interest falls into.



Entero Therapeutics Business Description

Traded in Other Exchanges
Address
777 Yamato Road, Suite 502, Boca Raton, FL, USA, 33431
First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.

Entero Therapeutics Headlines

No Headlines